<DOC>
	<DOCNO>NCT00326170</DOCNO>
	<brief_summary>5-aza chemotherapy drug activity leukemia myelodysplastic syndrome ( MDS ) . Researchers hope valproic acid ( VPA ) all-trans retinoic acid ( ATRA ) increase effect 5-aza . The goal clinical research study find high safe dose valproic acid ( VPA ) give combination 5-azacytidine ( 5-aza ) all-trans retinoic acid ( ATRA ) treatment AML MDS . The safety effectiveness combination therapy also study . Additional blood bone marrow sample request . These sample use evaluate effect treatment leukemic cell . In addition , leftover blood bone marrow sample collect start study regularly schedule evaluation send research study . The research study examine change blood bone marrow cell might help explain cause leukemia MDS combination 5-aza , VPA , ATRA work .</brief_summary>
	<brief_title>Phase II 5-Azacytidine Plus VPA Plus ATRA</brief_title>
	<detailed_description>Recent study show synergy demethylating agent histone deacetylase inhibitor . In laboratory , develop vitro model use HL-60 MOLT4 leukemic cell study effect combination decitabine ( 5-azacytidine analogue ) valproic acid . Valproic acid antiepileptic agent histone deacetylase inhibitory capacity . These result indicate addition valproic acid decitabine additive effect growth inhibition , induction apoptosis , induction p57KIP2 p21CIP1 expression independent cell cycle arrest . These result dependent dose duration treatment sequence use . Based data , develop phase I/II study combination decitabine valproic acid ( 2003-0314 ) patient leukemia show valproic acid safely administer dos 50 mg/kg orally 10 day combination decitabine , combination significant activity patient relapsed/refractory AML MDS . All-trans retinoic acid ( ATRA ) biological agent show induce cell differentiation leukemia cell line significant clinical activity acute promyelocytic leukemia minimal toxicity . In vitro , combination ATRA either hypomethylating agent histone deacetylase inhibitor show restore ATRA sensitivity resistant cell . More recently , German group report combination valproic acid ATRA activity patient MDS excellent toxicity profile . 5-azacytidine nucleoside analogue hypomethylating activity show randomize study benefit patient MDS , include improvement quality life . Based data , agent recently approve FDA use patient MDS , become first line agent patient MDS require therapy . The objective clinical trial following : - To determine maximal tolerate dose valproic acid ( VPA ) combination 5-azacytidine ( 5-aza ) all-trans retinoic acid . - To determine clinical activity combination 5-azacytidine , valproic acid all-trans retinoic acid patient AML MDS . - To determine vivo molecular biological effect combination . These include analysis change Deoxyribonucleic acid ( DNA ) methylation , histone modification , gene expression .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<criteria>Patients refractory relapse : acute myelogenous leukemia ( AML ) , myelodysplastic syndrome ( MDS ) ( bone marrow blast &gt; = 10 % ) eligible . Untreated patient old 60 year age AML MDS ( bone marrow blast &gt; = 10 % ) refuse eligible frontline chemotherapy , eligible . Performance status &lt; = 2 Eastern Cooperative Oncology Group ( ECOG ) scale . Signed informed consent indicate patient aware investigational nature study keep policy University Texas M D Anderson Cancer Center ( UTMDACC ) . Age &gt; 2 year . Valproic acid associate high rate severe liver toxicity child young 2 year . Patients must chemotherapy 2 week prior enter study recover toxic effect therapy , unless evidence rapidly progressive disease . Use hydroxyurea patient rapidly proliferative disease allow first two week therapy . Adequate liver function ( bilirubin &lt; 2mg/dL , SGPT &lt; 3 * ULN ) renal function ( creatinine &lt; 2mg/dL ) . Women childbearing potential must practice contraception . Men woman must continue birth control duration trial . Patients relapse /refractory disease inv16 , ( 8 ; 21 ) ( 15 ; 17 ) eligible . Nursing pregnant female exclude . Patients active uncontrolled infection exclude . Patients already receive valproic acid receive anticonvulsant exclude . Untreated patient young 60 year candidate study . Patients untreated disease inv16 , ( 8 ; 21 ) ( 15 ; 17 ) exclude .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Combination Chemotherapy</keyword>
	<keyword>MDS</keyword>
	<keyword>High-Risk Myelodysplastic Syndrome</keyword>
	<keyword>AML</keyword>
	<keyword>Acute myelogenous leukemia</keyword>
	<keyword>valproic acid</keyword>
	<keyword>VPA</keyword>
	<keyword>Depakene</keyword>
	<keyword>5-azacytidine</keyword>
	<keyword>5-aza</keyword>
	<keyword>Azacitidine</keyword>
	<keyword>5-AZC</keyword>
	<keyword>Vidaza</keyword>
	<keyword>AZA-CR</keyword>
	<keyword>Ladakamycin</keyword>
	<keyword>NSC-102816</keyword>
	<keyword>All-trans retinoic acid</keyword>
	<keyword>ATRA</keyword>
	<keyword>Tretinoin</keyword>
	<keyword>Vesanoid</keyword>
</DOC>